BTK and B-cell chronic lymphocytic leukemia: Simulation results of ibrutinib and BTK inhibition in CLL population showed that ibrutinib trough concentrations at daily doses from 280 mg were able to reduce the baseline BTK by at least 95% (Fig. 2).